Anavex Life Sciences (NASDAQ: AVXL) and Medgenics (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.
This table compares Anavex Life Sciences and Medgenics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-69.24%||-62.66%|
This table compares Anavex Life Sciences and Medgenics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anavex Life Sciences||N/A||N/A||-$13.46 million||($0.34)||-8.74|
Anavex Life Sciences is trading at a lower price-to-earnings ratio than Medgenics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Anavex Life Sciences has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Medgenics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for Anavex Life Sciences and Medgenics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||3||0||3.00|
Anavex Life Sciences presently has a consensus price target of $8.67, suggesting a potential upside of 191.81%. Medgenics has a consensus price target of $4.25, suggesting a potential upside of 109.36%. Given Anavex Life Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Anavex Life Sciences is more favorable than Medgenics.
Insider and Institutional Ownership
22.8% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 20.5% of Medgenics shares are owned by institutional investors. 12.1% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 15.2% of Medgenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Anavex Life Sciences beats Medgenics on 8 of the 10 factors compared between the two stocks.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Medgenics Company Profile
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.